Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol Myers Squibb focuses on products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Bristol Myers Squibb (BMS) and Bain Capital have announced the formation of a new independent biopharmaceutical company, referred to as NewCo. This venture aims to develop innovative therapies for autoimmune diseases, addressing significant patient needs that remain unmet.
NewCo will begin its operations with five immunology assets that have been in-licensed from BMS, supported by a $300 million financing commitment led by Bain Capital. The company’s pipeline includes three clinical-stage and two Phase I-ready investigational medicines, each targeting promising mechanisms in autoimmune diseases.
Among the most advanced assets in NewCo’s portfolio is afimetoran, an oral TLR7/8 inhibitor currently undergoing a Phase II clinical trial for systemic lupus erythematosus (SLE). Another key asset is BMS-986322, an oral TYK2 inhibitor that has shown positive results in a Phase II trial for plaque psoriasis, establishing proof-of-concept.
This strategic partnership between BMS and Bain Capital highlights a commitment to addressing the challenges faced by patients with autoimmune conditions through innovative therapeutic solutions.
We tailor your onboarding experience to match what you're looking for. Tell us more about yourself and your team to help us out.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
